In addition to blocking EGFR, Cetuximab also develops anti-tumour effects by provoking ADCC and inhibiting angiogenesis in vivo.38–40 Therefore, the anti-proliferative activity of Cetuximab in vivo is stronger than that in vitro. The gene discussed is EGFR; the disease is neoplasm.